IRLAB Therapeutics
13.5 SEK +3.85%2 investors are following this company
IRLAB Therapeutics is a Swedish research and pharmaceutical company. The research is based on the company's own research platform and specializes in the treatment of brain diseases, commonly referred to as neurodegenerative diseases. At the present, the company holds drug candidates specializing in, among other things, Parkinson's disease. The head office is located in Gothenburg.
Revenue
5.68M
EBIT %
-3,182.57 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
IRLAB A
Daily low / high price
13.2 / 13.8
SEK
Market cap
700.22M SEK
Turnover
268.81K SEK
Volume
20K
Latest videos
Financial calendar
Interim report
2024-07-10
Interim report
2024-10-30
Annual report
2025-02-14
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Avanza Pension | 9.4 % | 9.4 % |
Johnsson, Daniel | 8.7 % | 8.7 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
IRLAB's Phase IIb study of pirepemat can proceed as planned after positive opinion from external safety committee
IRLAB medverkar på Stora Aktiedagarna
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools